A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma

作者
Guang-Liang Chen,Yanjing Guo,Yanan Yang,Youzhou Sang,Si Sun,X Liu,X Y Zhou,Chun-ying Sheng,Xiayun He,Jianfei Wang,Rongliang Shi,Yu Wang,Q H Ji,Dongmei Ji
出处
期刊:npj precision oncology [Nature Portfolio]
卷期号:10 (1) 被引量:2
标识
DOI:10.1038/s41698-026-01463-5
摘要

Advanced salivary gland carcinoma (SGC) lacking both human epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) expression has limited treatment options. In this single-center, phase II trial, patients with recurrent/metastatic HER2-negative/AR-negative SGC received SHR-A1921, a TROP-2-directed antibody-drug conjugate, every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) per RECIST v1.1; secondary endpoints included progression-free survival (PFS), safety, and exploratory analyses of baseline TROP-2 expression by immunohistochemistry. As of August 1, 2025, 17 patients were treated and 15 were evaluable for efficacy, including 10 with non-adenoid cystic carcinoma (non-ACC) and 5 with adenoid cystic carcinoma (ACC). In non-ACC SGC, confirmed ORR was 20.0%, disease control rate was 80.0%, and clinical benefit rate was 60.0%. All patients with ACC achieved stable disease, with median PFS of 15.4 months. Treatment-related adverse events were manageable; oral mucositis was most common. No grade 4-5 treatment-related adverse events or treatment-related serious adverse events occurred; one patient discontinued treatment due to toxicity. Baseline TROP-2 expression was heterogeneous, with numerically higher H-scores in responders but no significant association with PFS. SHR-A1921 showed preliminary activity in non-ACC SGC and disease stabilization in ACC, supporting further evaluation in stratified cohorts. Trial registration: ClinicalTrials.gov, NCT05924256. Registered on June 29, 2023.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
59发布了新的文献求助10
刚刚
刚刚
HANA发布了新的文献求助10
刚刚
852的应助被Eric采纳,获得10
刚刚
白露完成签到 ,获得积分10
1秒前
1秒前
酷酷珠完成签到,获得积分10
2秒前
2秒前
嘻嘻哈哈的应助被luoshiyi采纳,获得10
2秒前
李恒发布了新的文献求助10
3秒前
无情向薇发布了新的文献求助10
3秒前
lllliiii发布了新的文献求助10
4秒前
4秒前
krzysku完成签到,获得积分10
5秒前
娜子完成签到,获得积分10
5秒前
5秒前
研狗发布了新的文献求助10
5秒前
隐形曼青的应助被HANA采纳,获得10
5秒前
6秒前
6秒前
温暖砖头发布了新的文献求助10
6秒前
小旋风发布了新的文献求助20
7秒前
7秒前
7秒前
苏苏完成签到,获得积分10
8秒前
8秒前
yy完成签到 ,获得积分10
8秒前
娜子发布了新的文献求助10
8秒前
白羽清风兮完成签到,获得积分10
8秒前
Gmj发布了新的文献求助10
9秒前
懵懂的飞飞完成签到,获得积分10
9秒前
9秒前
10秒前
ding的应助被李恒采纳,获得10
10秒前
wl完成签到,获得积分10
10秒前
平常的傲旋完成签到 ,获得积分10
11秒前
哈哈哈完成签到,获得积分10
12秒前
Eric发布了新的文献求助10
12秒前
zchhh完成签到 ,获得积分10
13秒前
花样年华发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046